Navigation Links
Generic Drugs: World Market Outlook 2011-2021
Date:11/2/2011

NEW YORK, Nov. 2, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generic Drugs: World Market Outlook 2011-2021

http://www.reportlinker.com/p0663864/Generic-Drugs-World-Market-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug

How will the market for generic drugs perform from 2011? Visiongain's report shows you potential revenues to 2021. Find opportunities and prospects there.

The world generics market has great potential to expand. Discover generic drug market revenues at total world and national levels. Through our research and analysis we aim to save you time and help in your decisions. 

Which national markets have the greatest potential? See how generics markets in the US, Japan, leading EU countries, India, China, Turkey, Brazil, Mexico, South Korea and the Russian Federation can perform to 2021, finding potential revenues.

Also, discover commercial prospects for companies such as Teva, Sandoz, Mylan, Apotex, Hospira and Watson. Receive information you need for the generics industry and market. 

In our report you receive discussions of regulations and opportunities. Assess prospects in off-patent drugs from 2011 onwards. Many more blockbusters will become vulnerable to generic competition. 

Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions

In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT) and opinions from our survey. You receive 84 tables and charts and two research interviews (see the table of contents).

Generic Drugs: World Market Outlook 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages in particular:

• Find potential revenues to 2021 for the world generic drugs market, seeing the possibilities there

• Assess leading generics companies, discovering their activities and outlooks

• See market forecasts to 2021 for the US, Japan, the UK, Germany, France, Spain, Italy, Turkey, Brazil, Mexico, South Korea, the Russian Federation, India and China

• Review developments in the generics industry and its regulation, finding trends

• Investigate competition and opportunities influencing the industry and market

• Find out what will stimulate and restrain the industry and market from 2011

• View opinion from our survey, receiving full interview transcripts.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions for generic drugs, helping you to stay ahead.

Order our report now to gain industry and market analysis for generic pharmaceuticals

Our report is for everybody needing industry and market analysis for generic drugs. Find trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

1.1 Generic Drugs: Industry and Market Review

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to the World Generics Market

2.1 Generic Drugs (Generics)

2.1.1 Authorised, Branded and True Generics

2.2 The 'Evergreening' of Pharmaceuticals

2.3 Restraints Facing the World Pharmaceutical Market

2.4 Branded Pharmaceuticals: End of a Business Model?

2.5 US Regulations

2.5.1 Obtaining FDA Approval: NDAs and ANDAs

2.5.2 The Hatch-Waxman Act Title 1: Promotion of Generic Drugs

2.5.3 The Hatch-Waxman Act Title 2: Incentives for the Branded Industry

2.5.4 Consequences of the Hatch-Waxman Act

2.5.5 Me First: Timing as a Crucial Factor

2.6 European Regulations

2.6.1 Generics' Entry into the European Markets

2.6.2 Further Protection of Branded Products in the European Market

2.6.3 Variations among European Countries

2.6.4 Moving Towards Standardisation

2.6.5 The 8+2+1 Rule

2.7 Japanese Regulations

2.8 Compulsory Licensing

2.9 Generic Drugs: Overview

3. The World Generic Drugs Market, 2011-2021

3.1 The World Generic Pharmaceuticals Market in 2010 

3.2 Generic Products to Benefit from Patent Expiries

3.2.1 Sales Forecast for the World Generic Drugs Market, 2011-2015

3.2.2 Sales Forecast for the World Generic Drugs Market, 2016-2021

3.3 Global Market Breakdown, 2011-2021

4. Leading Companies in the World Generics Market

4.1 Teva Pharmaceutical Industries - Prospects from 2011

4.1.1 ANDAs and Approvals

4.1.2 M&A Activity

4.2 Sandoz - Prospects from 2011

4.3 Mylan - Prospects from 2011

4.3.1 Mylan's Acquisition of Bioniche Pharma Holdings

4.4 Apotex - Prospects from 2011

4.5 Hospira - Prospects from 2011

4.5.1 Acquisition of Orchid's Generic Injectable Pharmaceutical Business

4.5.2 Hospira's Acquisition of Javelin Pharma

4.6 Watson - Prospects from 2011

4.6.1 ANDAs and Approvals

4.6.2 M&A Activity

4.6.3 Eden Becomes Wholly-Owned Subsidiary of Watson

4.6.4 Watson Acquires Specifar Pharmaceuticals

5. The US Generics Market 2011-2021

5.1 Analysis of the Current Market

5.2 The US Generics Market: Revenue Forecast 2011-2021

5.3 Regulatory Reform Can Keep the Market Growing 

5.3.1 A New Pathway to the US Market for Biosimilars?

5.3.2 Reverse Payments

5.3.3 The ANDA Backlog

5.4 Growing Consumer Acceptance of Generic Medicines

5.5 Leading Companies in the US Generics Market

5.6 Concluding Remarks

6. Leading European Generics Markets 2011-2021

6.1 Analysis of the Current Generics Market in Europe

6.2 Revenue Prospects for European Generics Markets 2011-2021

6.2.1 The Two Categories of European Market

6.2.2 European Pricing Systems and their Effect on Generic Penetration

6.2.3 Patient Co-Payment

6.2.4 Challenges with the European Regulatory Environment

6.3 The German Generics Market

6.3.1 German Generics Market: Sales Forecast 2011-2021

6.3.2 The Future of the German Generics Market

6.4 The French Generics Market

6.4.1 French Generics Market: Sales Forecast 2011-2021

6.4.2 The Future of the French Generics Market

6.5 The UK Generics Market

6.5.1 UK Generics Market: Sales Forecast 2011-2021

6.5.2 Generics Prescribing Linked to Increasing Budgetary Constraints

6.5.3 Reducing Generic Drug Prices: the Drug Tariff System

6.5.4 The Increasing Role of Pharmacists

6.5.5 Easy Entry, Strong Price Competition

6.5.6 The Future of the UK Generics Market

6.6 The Italian Generics Market

6.6.1 Italian Generics Market: Sales Forecast 2011-2021

6.6.2 Promoting Generic Penetration

6.6.3 Prospects for the Italian Generics Market

6.7 The Spanish Generics Market

6.7.1 Spanish Generics Market: Sales Forecast 2011-2021

6.7.2 Challenges for the Spanish Market

6.7.3 Prospects for the Spanish Generics Market

6.8 Concluding Remarks

7. The Japanese Generics Market 2011-2021

7.1 Analysis of the Current Market

7.2 Japanese Generics Market: Sales Forecast 2011-2021

7.3 Government Initiatives Have Driven Market Growth

7.3.1 Mergers and Acquisitions

7.4 Concluding Remarks

8. Emerging Generics Markets 2011-2021

8.1 The EM-7: Pharma's Best Hope

8.2 M&A as a Tactic for Entering the Generic Drugs Sector

8.3 Turkish Generics Market: Sales Forecast 2011-2021

8.4 Brazilian Generics Market: Sales Forecast 2011-2021

8.5 Mexican Generics Market: Sales Forecast 2011-2021

8.6 South Korean Generics Market: Sales Forecast 2011-2021

8.7 Russian Federation Generics Market: Sales Forecast 2011-2021

8.7.1 Russian Federation Generics Market, 2011-2021

8.7.2 Analysis of the Russian Federation Market

8.8 India - Market Prospects from 2011

8.8.1 Indian Generics Market: Sales Forecast 2011-2021

8.8.2 International Success of India's Pharmaceutical Industry

8.9 China - Market Prospects from 2011

8.9.1 Chinese Generics Market: Sales Forecast 2011-2021

8.9.2 Chinese Generics Market: Discussion of Sector

9. World Generics Market: Strengths, Weaknesses, Opportunities and Threats

9.1 The Generics Sector Will Remain a High-Growth Area

9.2 Generics Offer Limited Profitability

9.3 Emerging Markets and Generics: The Pharma Industry's Biggest Opportunity?

9.4 The Generic Drug Market's Growth is Assured, but Some Threats Remain

10. Opinions from Our Survey - Research Interviews

10.1 James Harris, CEO, Healthcare Economics LLC, Florida, USA

10.1.1 Main Challenges for the US Generics Market

10.1.2 Pricing Trends in Generic Products

10.1.3 On Authorised Generic Products

10.1.4 Current State of Biogeneric (Biosimilar) Legislation in the US

10.1.5 On Para 4 Challenges and Patent Cliff

10.1.6 On Generics Market in the Next Decade

10.2 Charlie Mayr, Generic Pharmaceutical Association (GPhA)

10.2.1 The Value of the Generics Market

10.2.2 Main Challenges for the US Generics Market

10.2.3 On Growth Trend in Generic Products

10.2.4 On US Pricing Trends in Generic Products

10.2.5 On Authorised Generic Products

10.2.6 On Biogeneric (Biosimilar) Products

11. Conclusions

11.1 The World Generics Market Will Continue to Expand

11.2 The Emerging National Markets Hold Much Promise

11.3 Biosimilars Have Promise, but Difficulties and Uncertainties Remain

11.4 Concluding Remarks

Appendices

Appendix A: Supplementary Information: Patent Expiries

Appendix B: About Visiongain

Appendix C: Visiongain Report Evaluation Form

List of Tables

Table 3.1 Generic Drugs Market: World Sales Forecast, 2010-2015

Table 3.2 Generic Drugs Market: World Sales Forecast, 2016-2021

Table 3.3 Generic Drugs Market: Developed Countries Sales Forecasts, 2010-2021

Table 3.4 Generic Drugs Market: Emerging Countries Sales Forecasts, 2010-2021

Table 4.1 Leading Companies in the World Generics Market: Sales and Market Shares, 2010

Table 4.2 The Top 10 Generics Market: M&A Deals, 2004-2010

Table 4.3 Sandoz Overview: Key Figures, 2010

Table 5.1 US Generic Drug Market Penetration (%) by Volume, 2000-2010

Table 5.2 US Generic Drug Market Penetration (%) by Revenue, 2000-2010

Table 5.3 US Generics Market: Sales Forecast, 2010-2015

Table 5.4 US Generics Market: Sales Forecast, 2016-2021

Table 6.1 German Generics Market: Sales Forecast, 2010-2015

Table 6.2 German Generics Market: Sales Forecast, 2016-2021

Table 6.3 French Generics Market: Sales Forecast, 2010-2015

Table 6.4 French Generics Market: Sales Forecast, 2016-2021

Table 6.5 UK Generics Market: Sales Forecast, 2010-2015

Table 6.6 UK Generics Market: Sales Forecast, 2016-2021

Table 6.7 Italian Generics Market: Sales Forecast, 2010-2015

Table 6.8 Italian Generics Market: Sales Forecast, 2016-2021

Table 6.9 Spanish Generics Market: Sales Forecast, 2010-2015

Table 6.10 Spanish Generics Market: Sales Forecast, 2016-2021

Table 7.1 Japanese Generics Market: Sales Forecast, 2010-2015

Table 7.2 Japanese Generics Market: Sales Forecast, 2016-2021

Table 8.1 Turkish Generics Market: Sales Forecast, 2010-2015

Table 8.2 Turkish Generics Market: Sales Forecast, 2016-2021

Table 8.3 Brazilian Generics Market: Sales Forecast, 2010-2015

Table 8.4 Brazilian Generics Market: Sales Forecast, 2016-2021

Table 8.5 Mexican Generics Market: Sales Forecast, 2010-2015

Table 8.6 Mexican Generics Market: Sales Forecast, 2016-2021

Table 8.7 South Korean Generics Market: Sales Forecast, 2010-2015

Table 8.8 South Korean Generics Market: Sales Forecast, 2016-2021

Table 8.9 Russian Federation Generics Market: Sales Forecast, 2010-2015

Table 8.10 Russian Federation Generics Market: Sales Forecast, 2016-2021

Table 8.11 Indian Generics Market: Sales Forecast, 2010-2015

Table 8.12 Indian Generics Market: Sales Forecast, 2016-2021

Table 8.13 Chinese Generics Market: Sales Forecast, 2010-2015

Table 8.14 Chinese Generics Market: Sales Forecast, 2016-2021

Table 9.1 SWOT Analysis of World Generic Drugs Market: Strengths and Weaknesses, 2011-2021

Table 9.2 SWOT Analysis of World Generic Drugs Market: Opportunities and Threats, 2011-2021

Table 11.1 Generic Drugs National Markets: Leading Developed Countries Sales Forecasts, 2010, 2012, 2015, 2017, 2019 & 2021

Table 11.2 Generic Drugs National Markets: Leading Emerging Countries Sales Forecasts, 2010, 2012, 2015, 2017, 2019 & 2021

Table A.1 Main Patent Expiries, 2011-2014

Table A.2 Main Patent Expiries by Number, 2011-2014

Table A.3 Main Patent Expiries, 2010

Table A.4 Main Patent Expiries, 2011

Table A.5 Main Patent Expiries, 2012

Table A.6 Main Patent Expiries, 2013

Table A.7 Main Patent Expiries, 2014

List of Figures

Figure 3.1 Generic Drugs Market: World Sales Forecast, 2010-2015

Figure 3.2 Generic Drugs Market: World Sales Forecast, 2016-2021

Figure 3.3 Generic Drugs Market: US and World Sales Forecasts, 2010-2021

Figure 3.4 Generic Drugs Market: Japan and Germany Sales Forecasts, 2010-2021 

Figure 3.5 Generic Drugs Market: Top Five EU Countries Sales Forecasts, 2010-2021

Figure 3.6 Generic Drugs Market: Emerging Countries Sales Forecasts, 2010-2021

Figure 3.7 Generic Drugs Market: Sales Shares in Leading National Markets, 2010

Figure 3.8 Generic Drugs Market: Sales Shares in Leading National Markets, 2015

Figure 3.9 Generic Drugs Market: Sales Shares in Leading National Markets, 2018

Figure 3.10 Generic Drugs Market: Sales Shares in Leading National Markets, 2021

Figure 4.1 Leading Companies in the World Generics Market, 2010

Figure 4.2 Teva's Sales Shares by Product Line, 2010

Figure 4.3 Mylan's Sales by Therapeutic Category, 2010

Figure 4.4 Hospira's Sales by Geographical Region, 2010

Figure 4.5 Watson's Sales by Geographical Region, 2010

Figure 4.6 Watson's Sales by Segment, 2010

Figure 5.1 US Generic Drug Market Penetration (%) by Volume, 2000-2010

Figure 5.2 US Generic Drug Market Penetration (%) by Revenue, 2000-2010

Figure 5.3 US Generics Market: Sales Forecast, 2010-2021

Figure 5.4 ANDAs Received, Approved and Tentatively Approved, 2005-2009

Figure 5.5 US Generics Market: Leading Companies by Prescription Volume, 2010

Figure 6.1 German Generics Market: Sales Forecast, 2010-2021

Figure 6.2 French Generics Market: Sales Forecast, 2010-2021

Figure 6.3 UK Generics Market: Sales Forecast, 2010-2021 

Figure 6.4 Italian Generics Market: Sales Forecast, 2010-2021

Figure 6.5 Spanish Generics Market: Sales Forecast, 2010-2021

Figure 7.1 Japanese Generics Market: Sales Forecast, 2010-2021

Figure 8.1 Turkish Generics Market: Sales Forecast, 2010-2021

Figure 8.2 Brazilian Generics Market: Sales Forecast, 2010-2021

Figure 8.3 Mexican Generics Market: Sales Forecast, 2010-2021

Figure 8.4 South Korean Generics Market: Sales Forecast, 2010-2021

Figure 8.5 Russian Federation Generics Market: Sales Forecast, 2010-2021

Figure 8.6 Indian Generics Market: Sales Forecast, 2010-2021

Figure 8.7 Chinese Generics Market: Sales Forecast, 2010-2021

Figure 11.1 Generic Drugs Market: US and World Sales Forecasts, 2010, 2012, 2015, 2017, 2019 & 2021

Figure 11.2 Generic Drugs Market: Leading Countries Sales Forecasts, 2010, 2012, 2015, 2017, 2019 & 2021 

Companies Listed

Abbott Laboratories

Ache Laboratórios Farmacêuticos

Actavis

Altra Investments

Amgen

Andrx Corporation

Apotex

APP Pharmaceuticals

Arrow Group

Asociacion Espanola de Fabricantes de Sustancias y Especialidades Farmaceuticas Genericas (AESEG)

Aspen

Assogenerici - Associazione Nazionale Industrie Farmaci Generici 

AstraZeneca

Aurobindo 

Aurobindo Pharma

Barr Pharmaceuticals

Bayer HealthCare

Bedford Laboratories

Beijing MedPharm

Bioniche Pharma Holdings 

Blue Cross Blue Shield Association (BCBSA)

BMP Sunstone

Boehringer Ingelheim

Bristol-Myers Squibb

British Generics Manufacturers Association (BGMA)

Cangene Corporation

Celltrion

Centers for Medicare and Medicaid Services

Cephalon 

Chon Kun Dang

Cipla

Claris Lifesciences

CoGenesys

Congressional Budget Office (CBO)

Corporacion Infarmasa [Peru]

Daiichi Sankyo

Dey Pharma

DOC Generici

Dr. Reddy's Laboratories

Ebewe Pharma

Eden Biodesign 

Egis

Eisai Pharmaceuticals

Eli Lilly

EMS Sigma Pharma

Eon Labs

Eurofarma Laboratorios

European Commission (EC)

European Court of Justice

European Generic Medicines Association (EGA)

European Medicines Agency (EMA/EMEA)

European Union (EU)

Famy Care

Farmacia del Ahorro

Farmacias Similares

Federal Trade Commission (FTC)

Food and Drug Administration (US FDA)

Fuji Pharma

Gedeon Richter

Genentech

Generic Pharmaceutical Association (GPhA)

German Association of Pharmacists (ABDA)

GlaxoSmithKline (GSK)

Glenmark Pharmaceuticals

Greenstone (Pfizer)

Healthcare Economics LLC

H. Lundbeck

Hospira

Hospira Healthcare India 

Intas Biopharmaceuticals

IVAX

Javelin Pharmaceuticals 

Johnson & Johnson

Jubilant Organosys

Kowa Pharmaceuticals

Krka

Laboratorios Best

Laboratorios Kendrick

Lareq Pharma

Lek Pharmaceuticals

Lupin Pharmaceuticals

MasterLek

Matrix

Matrix Laboratories 

Mayne Pharma

Medi-Mart

Medley Pharmaceuticals

Merck & Co.

Merck KGaA

Ministry of Health, Labour and Welfare (Japan)

Mundipharma International

Mylan Institutional 

Mylan Pharmaceuticals

Mylan Seiyaku

National Health Service (UK NHS)

Nichi-iko Pharmaceutical

Nippon Chemiphar

Novartis

NOVN. V Hexal

Onco Therapies

Orchid Chemicals & Pharmaceuticals 

Oriel Therapeutics

Pfizer

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmstandard

Piramal Healthcare

Pliva

Purdue Pharma

Ranbaxy Laboratories

Ratiopharm

Roche

Samsung

Sanborns

Sandoz

Sanofi (formerly sanofi-aventis)

Sawai Pharmaceuticals

Shire Pharmaceuticals

Sigma Pharmaceuticals

SK Chemicals

Stada Arzneimittel AG

Strides Arcolab 

Sun Pharmaceuticals

Taisho Pharmaceutical Industries

Taiyo Pharmaceuticals

Takeda Pharmaceutical Company

Tecnofarma

Teva Pharmaceutical Industries

The Rohatyn Group 

Theramex 

Topgen

Towa Pharmaceutical

UCB

UDL Laboratories 

UK Department of Health

Veropharm

Wal-Mart

Warner Chilcott

Watson Laboratories 

Watson Pharmaceuticals

Wockhardt

World Trade Organisation (WTO)

Wyeth

Zentiva

Zydus Cadila 

To order this report:

Generic Drug Industry: Generic Drugs: World Market Outlook 2011-2021

Generic Drug Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Multi-therapy Drugs: Opportunities for Generics & Biosimilars
2. Perrigo Announces Launch of Generic Version of Elestat®
3. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
4. Mylan Receives Approval for Generic Version of MS Contin® Tablets
5. FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers Access to Lower-Cost Generic Drugs
6. INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection
7. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
8. Par Pharmaceutical Begins Shipment of Generic Zyprexa® Zydis®
9. FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder
10. Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape
11. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  NOIT™ Research LLC, a private, ... of Change" campaign to assist needy families in obtaining ... unit sold between February 10, 2016 and March 31, ... needy family. The NOIT is an auditory stimulus that ... develop language skills. Beth Shier , ...
(Date:2/11/2016)... -- AfterPill.com is reporting that this week,s Centers for Disease ... who are at risk of unintended pregnancy impacts 43 ... the risks of unprotected sex in particular.  ... the Guttmacher Institute, there are 43 million women in ... have sex without the intention of becoming pregnant.  Despite ...
(Date:2/11/2016)... , 11 de fevereiro de 2016 /PRNewswire/ ... de sua fábrica de soroalbumina bovina (BSA -- ... A fábrica fica na Ilha Norte da Nova ... desenvolvido e estabelecido na fábrica da Proliant nos ... . O projeto e instalação dos equipamentos foram ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD CEO ... Garrett will focus on contract negotiations, corporate strategy and healthcare data law. Additional ... best practices in data breaches for the Part D Star Rating improvement and ...
(Date:2/11/2016)... Long Island, NY (PRWEB) , ... February 11, ... ... (INS) has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, ... global leader in vein illumination with an estimated 85% share of the market, ...
(Date:2/11/2016)... DC (PRWEB) , ... February 11, 2016 , ... The ... is based on evaluation of DataPoint’s team dedication and commitment to the ... companies comprising the annual list. The panel’s goal is to recognize and promote technology ...
(Date:2/11/2016)... Lake City, Utah (PRWEB) , ... February 11, ... ... the wireless microFET medical dynamometers and ergoFET force gauges used in physical therapy, ... RSI Rehab Strength Indicator sensor for resistance cord exercise and therapy, introduces its ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... significantly higher rates of several common cancer screenings, especially among women. Cancer screenings ... and survival rates. , The study,“What Does Medicaid Expansion Mean for Cancer ...
Breaking Medicine News(10 mins):